Below is an extract from the latest whitepaper, Life Sciences Trends 2026: The Era of the Smarter Operating Model by Bart Reijs and Simon Flowers:
2026 exposes a fundamental disconnect in the Life Sciences industry.
While biotech innovation is accelerating exponentially, the operating models designed to support it remain largely linear. Built for stability, not sustained volatility. Right now, the Life Sciences industry landscape is being reshaped by a set of ten deeply interconnected forces and trends:
Geopolitics as a core operational variable: Geopolitical volatility is now a direct driver of operational complexity. Life Sciences companies must manage fragmented regulations, regionalized supply chains, and data sovereignty constraints while embedding political risk into portfolio, M&A, and operating decisions.
Supply chain sovereignty for critical materials: Supply chain concentration is no longer tenable. Ensuring access to APIs and critical materials now requires sovereign, multi-source supply networks that trade cost efficiency for resilience and continuity.
The ascent of Chinese Life Sciences innovation: China’s rise as an innovation leader is redefining global competition. Western Life Sciences companies must adapt to faster development cycles, lower price points, and strategic uncertainty around their role in the Chinese market.
The therapeutic expansion beyond oncology: Life Sciences innovation is diversifying beyond oncology. Companies must manage distinct operational models across metabolic, neuroscience, and immunology therapies while maintaining efficiency and quality.
Operationalizing advanced therapies: Industrialization of advanced therapies is redefining operational capabilities. Success depends on scalable, automated manufacturing, robust supply chains, and regulatory-compliant production of complex therapies.
Technological convergence through agentic AI: Agentic AI is reshaping Life Sciences operations. Life Sciences organizations wanting to succeed require regulatory-compliant deployment, new workforce roles, and robust safeguards to manage operational, ethical, and IP risks.
Hybrid quantum computing entering applied biotech: Quantum technologies are moving from theory to applied biotech. Organizations must develop expertise, engage with the ecosystem, and secure data today to avoid being outflanked as the field matures.
Multi-omics becoming clinical reality: Multi-omics is becoming clinically actionable. Industry leaders must build infrastructure and expertise to integrate complex molecular data into real-time patient care and clinical decision-making.
Demographic frontiers driving FemTech and silver economy innovation: Women’s health and aging populations are reshaping Life Sciences priorities. Operational models must support targeted therapies, digital care, and economically sustainable approaches for these growing patient groups.
Commercial agility through direct engagement: Pharma commercial models are shifting toward direct patient engagement. Success depends on digital infrastructure, regulatory compliance, and patient-centric operations that reclaim value and generate actionable real-world data.
Each of these forces demands significant operational adaptation on its own. Taken together, they create compounding complexity that overwhelms traditional operating approaches. Life Sciences organizations optimized for predictable growth now face continuous disruption across clinical development, manufacturing, supply chains, and commercial execution.
In response, leading Life Sciences organizations are converging on what we define as the Smarter Operating Model. This is not an incremental evolution, but a fundamental redesign of how the enterprise operates. It is digitally integrated, scenario-driven, and AI-enabled. This allows organizations to move from reactive decision-making to proactive orchestration.
Life Sciences companies adopting this model are already reducing decision latency from days to hours, strengthening supply chain resilience through predictive intelligence, deploying AI safely within regulatory boundaries, and aligning clinical, manufacturing, and commercial functions around shared, real-time signals.